Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Biomarkers & Companion Diagnostics

PART OF BIOMARKERS, CDx & PRECISION MEDICINE US

23 - 24 September 2026 | Gaylord Pacific Resort & Convention Center, San Diego, CA

Programme Summary

The Biomarkers & Companion Diagnostics programme covers the earliest decisions in the precision medicine decision chain: biomarker discovery and validation, CDx development, regulatory pathways for AI-derived biomarkers and AI/ML-based diagnostics, liquid biopsy strategies, patient stratification, and the oncology biomarker programmes currently being run inside the largest biopharma R&D organisations.

Across two days and three tracks per day, the programme sits alongside the senior US regulatory line-up on AI-derived biomarkers and CDx development. Cross-programme sessions then connect biomarker work directly to the multi-omics methods and computational pathology platforms operating around it, so delegates leave with a view of where their programmes fit inside the wider precision medicine landscape. 

Programme Image 1

Day 1 Plenary Keynote

HOIFUNG POON, General Manager, Microsoft Research

Hoifung Poon leads health AI research at Microsoft Research, focused on AI for accelerating biomedical discovery. His work spans foundation models for biomedicine, real-world evidence at scale, and how AI changes what biomedical researchers can do across the discovery-to-clinic pipeline. He opens Day 1 of Biomarkers, CDx & Precision Medicine US 2026 on AI for accelerating medical discovery. 

Hoifung Poon Headshot

2026 Highlights

A cross-programme regulatory panel brings Reena Philip (Executive Director, Regulatory Liaison CDx/IVDx, Merck), Karen McCullough (VP Oncology Regulatory Strategy, AstraZeneca) FDA representation into one conversation on what the agency actually expects from AI-derived biomarkers and CDx in 2026.

Track keynotes from Andrea Ferreira-Gonzalez (Virginia Commonwealth) on multi-cancer early detection, Hebe Sun (Regeneron) on the CDx regulatory framework in the US and EU, and Sapna Yadavilli (GSK) on preclinical strategies for clinical translation.

Plus sessions on liquid biopsy, patient stratification, oncology biomarker validation, and the operational reality of CDx co-development. 

Our Community and Culture Circle Image
NextGen Biomed - What to Expect Networking 4
600

leading pharma, biotech, regulatory & academic delegates

200
hours of pre-arranged 1-2-1 meetings, facilitating business growth
50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including fireside chats & refreshments

Biomarkers & Companion Diagnostics Agenda at a Glance

DAY ONE

Track 1: Biomarker Identification, Qualification & Validation in Oncology & IO
Track 2: Companion Diagnostics & Regulations Track 3: Biomarkers in Translational & Clinical Development

DAY TWO

Track 1:  Biomarker Identification, Qualification & Validation Across Therapeutic Areas
Track 2: Technologies for Biomarker Analysis Track 3: Biomarkers for Clinical Trials & Personalized Patient Treatment

BIOMEU On Page Agenda

Featured Speakers for Biomarkers & Companion Diagnostics US 2026

Hoifung Poon
General Manager, Microsoft Research,
Microsoft Corporation
Olivier Harismendy
Vice President,
Zentalis Pharmaceuticals
Sapna Yadavilli
Executive Director, Early Program Biomarkers Team,
GSK
Show More Speakers
Hide Speakers
Andrea Ferreira-Gonzalez
Professor,
Virginia Commonwealth University School of Medicine
David Weingeist
Scientific Director,
Janssen Pharmaceutical Companies of Johnson & Johnson
Dorothy French
Executive Director of Translational Pathology in Clinical Biomarkers & Diagnostics,
Amgen
Hebe Sun
Associate Director, Regulatory Affairs CDx,
Regeneron
Hua Gong
Vice President, Translational Medicine,
BridgeBio Oncology Therapeutics
Janell Cleveland
Senior Patent Agent,
MCCIP
Javier Perez
Senior Director, Precision Medicine Dx and Digital Pathology (DP/AI) Strategy - Oncology,
Regeneron
Kenneth Ramos
Executive Director,
Texas A&M University
Minnie Sarwal
Professor,
University of California San Francisco
Pablo Tamayo
Professor, Division of Genomics and Precision Medicine,
UCSD School of Medicine
Petar Pop-Damkov
Director, Bioanalytical Strategy Lead, AstraZeneca,
CRUK AstraZeneca Antibody Alliance Laboratory
Sri Venkatram
Director II CDx Strategy Team Lead,
AbbVie
Yasser Riazalhosseini
Associate Professor,
University of McGill
Yong Zeng
Professor,
Department of Chemistry

Interested in Sponsoring Biomarkers & Companion Diagnostics?

Connect with 600+ senior pharma R&D leaders, translational scientists, multi-omics platform heads and spatial biology programme leads. 74% of delegates at the last edition were actively seeking new solutions, with over half with allocated budget.

Pre Med + LSX Combined Logo

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things Precision Medicine, direct to your inbox.

Pre Med Newsletter Icon-1

Partner With Us

Position your company in front of the senior US biomarker and CDx audience: discovery leads, validation teams, regulatory voices and CDx programme heads from the largest biopharma R&D organisations. Sponsorship options include presentation slots, exhibition space, branded sessions and pre-arranged 1:1 meetings. 

Register Now

Two days of senior R&D, regulatory and CDx conversations.
San Diego. 23 – 24 September 2026. 


Key Event Highlights

An unmissable journey awaits you: from celebrated keynote speakers and insightful private roundtables, to an exclusive gala dinner. Discover the moments that will transform your NextGen Omics & Spatial experience. 

Decision 1

Sentence describing Decision 1

Decision 2

Sentence describing Decision 2